Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Car-Seller Copart Is Among Suitors for Car Insurance Software Firm CCC (Bloomberg) +++ CCC INTELLIGENT Aktie +4,66%

REGENERON Aktie

 >REGENERON Aktienkurs 
703.8 EUR    +1.1%    (TradegateBSX)
Ask: 702 EUR / 90 Stück
Bid: 700.6 EUR / 90 Stück
Tagesumsatz: 176 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
REGENERON Aktie über LYNX handeln
>REGENERON Performance
1 Woche: -0,1%
1 Monat: +18,3%
3 Monate: +15,9%
6 Monate: +5,2%
1 Jahr: +40,7%
laufendes Jahr: +5,2%
>REGENERON Aktie
Name:  REGENERON PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US75886F1075 / 881535
Symbol/ Ticker:  RGO (Frankfurt) / REGN (NASDAQ)
Kürzel:  FRA:RGO, ETR:RGO, RGO:GR, NASDAQ:REGN
Index:  S&P500, Nasdaq100
Webseite:  https://www.regeneron.com..
Profil:  Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases across eye care, immunology, oncology, cardiovascular health, and inflammation. Its current portfolio in..
>Volltext..
Marktkapitalisierung:  71500.61 Mio. EUR
Unternehmenswert:  66878.07 Mio. EUR
Umsatz:  13427.35 Mio. EUR
EBITDA:  4064.5 Mio. EUR
Nettogewinn:  3741.49 Mio. EUR
Gewinn je Aktie:  36.22 EUR
Schulden:  2339.44 Mio. EUR
Liquide Mittel:  2131.48 Mio. EUR
Operativer Cashflow:  4046.26 Mio. EUR
Bargeldquote:  1.45
Umsatzwachstum:  12.73%
Gewinnwachstum:  0.14%
Dividende je Aktie:  2.37 EUR
Dividendenrendite:  0.45%
Dividendenschätzung:  0.47%
Div. Historie:  20.05.26 - 0.808306€
20.02.26 - 0.798906€
>weitere anzeigen...
Insiderhandel:  2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 829.245 Euro.
Suchwörter:  REGENERON
Letzte Datenerhebung:  18.08.26
>REGENERON Kennzahlen
Aktien/ Unternehmen:
Aktien: 101.14 Mio. St.
Frei handelbar: 97.98%
Leerverk. Aktien: 3.35%
Rückkaufquote: 3.07%
Mitarbeiter: 15410
Umsatz/Mitarb.: 0.8 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 4.85%
Bewertung:
KGV: 19.6
KGV lG: 14.85
KUV: 5.35
KBV: 2.59
PEG-Ratio: 9.91
EV/EBITDA: 16.45
Rentabilität:
Bruttomarge: 81.46%
Gewinnmarge: 27.86%
Operative Marge: 26.87%
Managementeffizenz:
Gesamtkaprendite: 10.83%
Eigenkaprendite: 14.04%
>REGENERON Peer Group
 
18.08.26 - 16:12
 REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm (PR Newswire)
 
NEW YORK, Aug. 18, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead......
18.08.26 - 12:27
 Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP (PR Newswire)
 
SAN FRANCISCO, Aug. 18, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
17.08.26 - 09:33
 Bayer-Partner Regeneron überrascht – jetzt kaufen? (Der Aktionaer)
 
In den vergangenen Wochen hat eine ganze Reihe von Pharma- und Biotech-Unternehmen die Zahlen für das zurückliegende Quartal vorgelegt. DER AKTIONÄR verrät, wer am besten abgeschnitten hat und wie Regeneron nach dem Rücksetzer im Mai nun dasteht und ob man bei der Aktie jetzt zugreifen sollte....
16.08.26 - 21:36
 XETR: DIVIDEND/INTEREST INFORMATION - 18.08.2026 - US75886F1075 (XETRA)
 
Das Instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY wird cum Dividende/Zinsen gehandelt am 17.08.2026 und ex Dividende/Zinsen am 18.08.2026 The instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY has its pre-dividend/interest day on 17.08.2026 and its ex-dividend/interest day on 18.08.2026...
14.08.26 - 21:36
 Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman (PR Newswire)
 
SAN FRANCISCO, Aug. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
13.08.26 - 18:54
 REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt (PR Newswire)
 
This timeline-focused notice highlights allegations that Regeneron's Phase III Fianlimab-Libtayo disclosures evolved from delayed event accrual to a protocol amendment and then a failed primary endpoint, with REGN investors allegedly absorbing substantial share-price losses. NEW YORK, Aug.......
13.08.26 - 16:03
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN (PR Newswire)
 
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or......
13.08.26 - 01:01
 Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 640000 USD (Insiderkauf)
 
Zoghbi, Huda Y. - Aufsichtsrat - Tag der Transaktion: 2026-08-10...
13.08.26 - 01:01
 Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 320000 USD (Insiderkauf)
 
Guarini, Kathryn - Aufsichtsrat - Tag der Transaktion: 2026-08-10...
12.08.26 - 21:21
 Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP (PR Newswire)
 
SAN FRANCISCO, Aug. 12, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
12.08.26 - 16:12
 REGN DEADLINE: Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline (PR Newswire)
 
Control-person liability allegations focus on Regeneron executives' alleged authority over public clinical-trial statements and SEC disclosures as REGN shares fell $102.09 from the Class Period high. NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in......
12.08.26 - 12:57
 Regeneron, Tenet leads top healthcare companies with highest earnings beats (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
11.08.26 - 16:09
 REGN DEADLINE: The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline (PR Newswire)
 
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead......
11.08.26 - 14:06
 Infinimmune Raises $75 Million Series A Financing to Advance Pipeline of Human-Derived Antibodies for Atopic Dermatitis and Inflammatory Disease (Business Wire)
 
Series A co-led by Regeneron Ventures and Playground Global, with participation from RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital, Merck Global Health Innovation Fund, and Everbright Biofund Pipeline includes two wholly owned, half-life extended monoclonal antibodies targeting complementary pathways in atopic dermatitis, both expected to enter the clinic in 2027 ALAMEDA, Calif.--(BUSINESS WIRE)--#AI--Infinimmune, a biotechnology company developing antibody therapeutics derived directly from the human immune system, today announced the closing of a $75 million Series A financing co-led by Regeneron Ventures and Playground Global with participation from RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital, and Wild Tree Ventures. Existing investors Merck Global Health Innovation Fund, Everbright Biofund, Civilization Ventures, and Pear VC also participated. The financing will accelerate clinical development of Infinimmune's two lea...
11.08.26 - 12:33
 REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit (PR Newswire)
 
SAN FRANCISCO, Aug. 11, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
10.08.26 - 14:18
 Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP (PR Newswire)
 
SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
07.08.26 - 18:15
 NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues (Zacks)
 
Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results....
07.08.26 - 04:03
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN (PR Newswire)
 
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980,......
06.08.26 - 20:00
 REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit (PR Newswire)
 
SAN FRANCISCO, Aug. 6, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
05.08.26 - 19:45
 Surging Earnings Estimates Signal Upside for Regeneron (REGN) Stock (Zacks)
 
Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Fälle weder den ganzen Wald, noch komm ohne Holz nach Hause. - Sprichwort Serbien
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!